TRIALS FOR PHOTODYNAMIC THERAPY (PDT)
TAP STUDY ( P for PDT & Predominantly classic CNVM) :
- PDT vs Sham group in Predominantly classic CNVM.
- Showed statistically significant benefit in predominantly classic CNVM.
VIP STUDY ( P for PDT; VIPs are Occult)
- PDT vs placebo
- Included patients with Occult CNVM without classic component.
- No significant benefit in visual acuity.
Conclusion : PDT is effective only in Predominantly Classic CNVM.
TRIALS FOR PEGAPTANIB (MACUGEN)
- Pegaptanib is VEGF-165 inhibitor.
- First FDA approved drug for treatment of AMD in 2004.
- Got approval on the basis of VISION( VEGF inhibitor study in ocular neovascularisation) trial.
- KEY : VISION = MACULA (macugen).
VISION TRIAL:
- Intravitreal Macugen (0.3 mg, 1mg & 3mg) vs sham injection at 6 weekly interval.
- 0.3 mg dose proved to be more effective than 1mg and 3mg injections and sham injections with statistically significant reduction in moderate to severe visual acuity loss over 2 years of follow up.
TRIALS FOR RANIBIZUMAB (LUCENTIS)
- FDA approved in 2006 on the basis of the results of MARINA & ANCHOR TRIALS.
- First FDA approved anti VEGF agent that has shown improvement in visual acuity in all isoforms of CNVM and prevented leakage and further growth of the lesion.
MARINA TRIAL ( Minimally classic/Occult CNVM anti VEGF Ranibizumab in Neovascular AMD).
- Intravitreal Ranibizumab (0.3 & 0.5 mg) monthly injection in minimally classic or occult CNVM vs sham group.
- Statistically significant reduction in visual acuity loss along with improvement in visual acuity over 1 year of follow up.
- Clinical improvement was associated with improved angiographic and OCT picture.
ANCHOR STUDY ( Anti VEGF Ranibizumab for the treatment of predominantly Classic CNVM in neovascular AMD ).
- PDT controlled trial
- 0.3 & 0.5 mg intravitreal Ranibizumab monthly injection vs 3 monthly PDT in Classical CNVM.
- Statistically significant reduction in visual acuity loss along with improvement in visual acuity with 0.5 mg Ranibizumab over 2 year of follow up as compared to PDT.
PIER STUDY ( R for Ranibizumab)
- 3 consecutive monthly injections of Ranibizumab followed by 3 monthly injection.
- Improvement in visual acuity observed during first 3 months which was not sustained after discontinuance of monthly injections over 1 year of follow up.
PRONTO TRIAL ( Prospective OCT imaging of patient with Neovascular AMD treated with intraocular Ranibizumab )
- 3 consecutive monthly injections of Ranibizumab followed by monthly OCT evaluation.
- Injections repeated only when OCT showed progression.
- Comparable visual acuity outcomes with ANCHOR & MARINA trials.
TRIALS FOR BEVACIZUMAB (AVASTIN)
- FDA approved in 2004 for systemic use in colorectal cancer.
- 5mg/kg intravenous also tried in AMD cases, 3 injections @ 2 weekly interval, later injections were OCT guided.
- 5mg/kg I.V dose.
- Advantage of systemic Avastin - bilateral disease can be treated.
- Increased B.P controllable with medication was the only reported adverse effect.
- First intravitreal Avastin was given in May 2005, has shown comparable results with systemic Avastin and intravitreal Ranibizumab.
- Comparison between intravitreal Avastin and Lucentis in all isoforms of neovascular AMD.
- Both came out to be equally effective in the treatment of all isoforms of neovascular AMD.